Induced Th2 dominant immune response in APPswe, PSEN1dE9 transgenic mice after nasal immunization with an adenoviral vector encoding 10 tandem repeats of beta-amyloid 3-10
查看参考文献30篇
文摘
|
Immunotherapy for Alzheimer’s disease (AD) is effective in improving cognitive function in transgenic mouse models of AD. Because the AN1792 [beta-amyloid (Aβ) 1-42] vaccine was halted because of T cell mediated meningoencephalitis, many scientists are searching for a novel vaccine to avoid the T cell mediated immune response caused by the Aβ1-42. Importantly, the time when the immunization is begun can influence the immune effect. In this study, an adenovirus vaccine was constructed containing 10 × Aβ3-10 repeats and gene adjuvant CpG DNA. Transgenic AD mice were immunized intranasally for 3 months. After 10 × Aβ3-10 vaccine immunization, high titers of anti-Aβ42 IgG1 predominant antibodies were induced. In spatial learning ability and probe tests, the 10 × Aβ3-10 immunized mice showed significantly improved memories compared to control mice. The 10 × Aβ3-10 vaccine resulted in a robust Th2 dominant humoral immune response and reduced learning deficits in AD mice. In addition, the 10 × Aβ3-10 vaccine might be more efficient if administered before Aβ aggregation at an early stage in the AD mouse brain. Thus, the adenovirus vector encoding 10 × Aβ3-10 is a promising vaccine for AD |
来源
|
Neural Regeneration Research
,2011,6(26):2005-2012 【核心库】
|
DOI
|
10.3969/j.issn.1673-5374.2011.26.001
|
关键词
|
Alzheimer's disease
;
immunotherapy
;
gene vaccine
;
amyloid plaque
;
T cell immunity response
;
neural regeneration
|
地址
|
1.
Department of Neurology, First Affiliated Hospital of China Medical University, Liaoning, Shenyang, 110001
2.
Department of Neurology, Shenyang Red Cross Hospital, Liaoning, Shenyang, 110013
3.
Department of Neurology, First Affiliated Hospital of Liaoning Medical College, Liaoning, Jinzhou, 121001
|
语种
|
英文 |
文献类型
|
研究性论文 |
ISSN
|
1673-5374 |
学科
|
神经病学与精神病学 |
基金
|
国家自然科学基金
|
文献收藏号
|
CSCD:4363505
|
参考文献 共
30
共2页
|
1.
Wolfe M S. Shutting down Alzheimer’s.
Sci Am,2006,294(5):72-79
|
CSCD被引
2
次
|
|
|
|
2.
Schenk D. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse.
Nature,1999,400(6740):173-177
|
CSCD被引
129
次
|
|
|
|
3.
Orgogozo J M. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization.
Neurology,2003,61(1):46-54
|
CSCD被引
33
次
|
|
|
|
4.
Nicoll J A. Neuropathology of human Alzheimer’ disease after immunization with amyloid-beta peptide a case report.
Nat Med,2003,9(4):448-452
|
CSCD被引
38
次
|
|
|
|
5.
Ferrer I. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.
Brain Pathol,2004,14(1):11-20
|
CSCD被引
12
次
|
|
|
|
6.
Holmes C. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
Lancet,2008,372(9634):216-223
|
CSCD被引
39
次
|
|
|
|
7.
Vellas B. Long-term follow-up of patients immunized with AN1792:reduced functional decline in antibody responders.
Curr Alzheimer Res,2009,6(2):144-151
|
CSCD被引
8
次
|
|
|
|
8.
Mclaurin J. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.
Nat Med,2002,8(11):1263-1269
|
CSCD被引
25
次
|
|
|
|
9.
Monsonego A. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease.
J.Clin Invest,2003,112(3):415-422
|
CSCD被引
21
次
|
|
|
|
10.
Frenkel D. Generation of auto-antibodies towards Alzheimer’s disease vaccination.
Vaccine,2001,19(17/19):2615-2619
|
CSCD被引
11
次
|
|
|
|
11.
Kim H D. Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid β-protein and GM-CSF.
Vaccine,2005,23(23):2977-2986
|
CSCD被引
7
次
|
|
|
|
12.
Kim H D. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Aβ1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer disease.
J Gene Med,2007,9(2):88-98
|
CSCD被引
6
次
|
|
|
|
13.
Yamamoto S. CpG motif and tuberculosis immunity.
Kekkaku,2010,85(6):515-522
|
CSCD被引
1
次
|
|
|
|
14.
Weiner H L. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in amouse model of Alzheimer’s disease.
Ann Neurol,2000,48(4):567-579
|
CSCD被引
7
次
|
|
|
|
15.
Cribbs D H. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with betaamyloid.
Int Immunol,2003,15(4):505-514
|
CSCD被引
17
次
|
|
|
|
16.
Lemere C A. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer’s disease.
DNA Cell Biol,2001,20(11):705-711
|
CSCD被引
4
次
|
|
|
|
17.
Bowers W J. Amyloid immunotherapy-engendered CNS inflammation.
Neurobiol Aging,2002,23(5):683-674
|
CSCD被引
1
次
|
|
|
|
18.
Lemere C A. Developing novel immunogens for a safe and effective Alzheimer’s disease vaccine.
Prog Brain Res,2009,175:83-93
|
CSCD被引
7
次
|
|
|
|
19.
Seabrook T J. Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice.
J Neuroinflammation,2006,3:14
|
CSCD被引
1
次
|
|
|
|
20.
Maier M. Short Amyloid-β(Aβ) immunogens reduce cerebral Aβ load and learning deficits in an Alzheimer’s disease mouse model in the absence of an Aβ-specific cellular immune response.
J Neurosci,2006,26(18):4717-4728
|
CSCD被引
6
次
|
|
|
|
|